Advertisement
Advertisement
U.S. Markets open in 46 mins
Advertisement
Advertisement
Advertisement
Advertisement

Acumen Pharmaceuticals, Inc. (ABOS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.58+4.88 (+103.83%)
At close: 04:00PM EDT
8.89 -0.69 (-7.20%)
Pre-Market: 08:44AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.70
Open8.10
Bid8.79 x 1200
Ask0.00 x 1100
Day's Range7.28 - 10.23
52 Week Range3.02 - 15.64
Volume64,655,152
Avg. Volume1,082,533
Market Cap387.705M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.67
  • Simply Wall St.

    We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Motley Fool

    Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript

    Thank you for standing by, and welcome to the Acumen Pharmaceuticals second quarter 2022 update call. Thank you for joining us today to review Acumen's second quarter 2022 update on operational progress and financial results. Before we start, we encourage you to read the operational and financial results press release issued this afternoon, which is accessible on our website in the Investors section.

  • GlobeNewswire

    Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

    Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD)Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AβOs) presented in a poster at the recent Alzheimer’s Association International Conference (AAIC)$209.9 million in cash, cash equivalents and

Advertisement
Advertisement